New eczema foam shows promise for kids in Late-Stage trial
NCT ID NCT07184645
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tests a medicated foam called OPA-15406 (difamilast) for atopic dermatitis (eczema) in children aged 2 and older, and infants under 2. About 198 participants will apply the foam twice daily for 8 weeks. The main goal is to see if the foam clears or nearly clears skin symptoms better than a foam without medicine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OPA-15406 (difamilast) foam
What this could lead to
If successful, this could provide a new topical treatment option for children and infants with atopic dermatitis, potentially improving skin symptoms and quality of life.
What could go wrong
This is still an early-stage Phase 3 trial with only 198 participants, so results may not apply to all patients. The treatment may not prove superior to the vehicle (placebo) foam, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
Locations
-
Sumire Dermatology Clinic
Tokyo, Japan